Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
By J. Kuebler, H. Wieand, M. O’connell, Roy E. Smith, L. Colangelo, G. Yothers, N. Petrelli, M. Findlay, T. Seay, J. Atkins and 11 more. Journal of Clinical Oncology, 2007
1,038 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/90a4d369009bb4fa30be830236f2bdc2b95dd475
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. (2009, methodology): “The National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial also evaluated the addition of oxaliplatin to an alternative FL schedule (weekly Roswell Park regimen of bolus FL) as adjuvant therapy after surgery in a similar population of patients with stage II or III colon cancer.(19) A”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, background): “• Randomized controlled trials conducted in Europe and the United States have shown that the combination of intravenous infusion of 5-FU ? LV and L-OHP (FOLFOX4 and FLOX) used as postoperative adjuvant chemotherapy for stage III colon cancer provides an additional benefit in terms of prevention of r”
- Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. (2011, methodology): “002, DFS remained significantly different by treatment in the full cohort of this study, which is consistent with the original report of this study.(2) The HR for FLOX versus FULV was 0.”
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, result): “6% for FLOX and FULV, respectively [31], and the magnitude of reduction in the risk of recurrence was similar to that of the MOSAIC trial.”
- Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. (2020, result): “All showed significant improvement in DFS compared with fluoropyrimidine as single agent [69-71].”
- Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. (2009, methodology): “FU with leucovorin became standard of care for patients with stage III and selected stage II colon cancer in the early 1990s(1-4) and provided the basis for the addition of oxaliplatin, which has been demonstrated to further improve disease-free survival (DFS) and OS in stage III patients.(5,6) Alth”